東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

A history of a cGMP medical event in...

Brown, Michael A., (1945-)

FindBook

Google Book

Amazon

博客來

A history of a cGMP medical event investigation

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	A history of a cGMP medical event investigation/ Michael A. Brown.
作者:	Brown, Michael A.,
出版者:	Hoboken, N.J. :John Wiley & Sons, : c2013.,
面頁冊數:	1 online resource (253 p.)
標題:	Adverse Drug Reaction Reporting Systems - United States. -
電子資源:	http://onlinelibrary.wiley.com/book/10.1002/9781118494943
ISBN:	9781118494943 (electronic bk.)

A history of a cGMP medical event investigation
Brown, Michael A.,1945-

A history of a cGMP medical event investigation[electronic resource] /Michael A. Brown. - Hoboken, N.J. :John Wiley & Sons,c2013. - 1 online resource (253 p.)

Includes bibliographical references and index.

Beginning with the untimely death of a young mother, A History of a cGMP Medical Event Investigation unfolds a fictitious case study that captures how unchecked human flaws during the development and launch of a new drug can lead to disastrous consequences. Moreover, it illustrates how and why Six Sigma principles and methods should be applied to fully comply with FDA regulations at every stage of drug development and commercialization. From initial transgenic mouse studies to the FDA fatality investigation, this case study introduces all the key regulations and practices that govern the development, manufacture, and marketing of a new drug, including: [1] FDA Investigational and New Drug Application Processes, [2] FDA Code of Federal Regulations' current Good Manufacturing Practice (cGMP), [3] ISPE Good Automated Manufacturing Practice (GAMP) Readers will also be introduced to a variety of managers and researchers whose personal agendas conflict with best practices and therefore compromise the safety and effectiveness of a new drug product. Throughout the case study, the author offers tested and proven practices and tips so that these human flaws are not translated into drug product flaws. These practices and tips are critical and typically can only be learned through years of experience working in competitive drug development environments. A History of a cGMP Medical Event Investigation is ideal for students in biotechnology, pharmacology, engineering, and business management as well as professionals in biomedical and drug development. All readers will discover what can go wrong in developing and bringing a new drug to market. Most importantly, they will also learn how to apply Six Sigma principles and methods to ensure safe and effective product design, development, and manufacturing.

ISBN: 9781118494943 (electronic bk.)Subjects--Corporate Names:

758649
United States.
Food and Drug Administration.Subjects--Topical Terms:

832845
Adverse Drug Reaction Reporting Systems
--United States.

LC Class. No.: RM302.5 / .B76 2013

Dewey Class. No.: 615.58

National Library of Medicine Call No.: QV 26.5 / B76 2013

A history of a cGMP medical event investigation
LDR:03046cmm a2200349Ia 4500 001 2002714
003 OCoLC
005 20141003035657.0
006 m o d
007 cr |||||||||||
008 151223s2013 nju ob 001 0 eng d
020 $a 9781118494943 (electronic bk.)
020 $a 1118494946 (electronic bk.)
020 $a 9781118494936 (electronic bk.)
020 $a 1118494938 (electronic bk.)
020 $z 9781118396612 (paper)
020 $z 1118396618 (paper)
020 $a 9781118494882 (electronic bk.)
020 $a 1118494881 (electronic bk.)
035 $a (OCoLC)823645667 $z (OCoLC)864914126
035 $a ocn823645667
040 $a N $c N $d YDXCP $d E7B $d CDX $d IDEBK $d OCLCA $d ORE $d RECBK $d OCLCO $d DG1 $d UKDOC $d OCLCF
043 $a n-us---
050 4 $a RM302.5 $b .B76 2013
060 1 4 $a QV 26.5 $b B76 2013
082 0 4 $a 615.58 $2 23
100 1 $a Brown, Michael A., $d 1945- $3 2147335
245 1 2 $a A history of a cGMP medical event investigation $h [electronic resource] / $c Michael A. Brown.
260 $a Hoboken, N.J. : $b John Wiley & Sons, $c c2013.
300 $a 1 online resource (253 p.)
504 $a Includes bibliographical references and index.
520 $a Beginning with the untimely death of a young mother, A History of a cGMP Medical Event Investigation unfolds a fictitious case study that captures how unchecked human flaws during the development and launch of a new drug can lead to disastrous consequences. Moreover, it illustrates how and why Six Sigma principles and methods should be applied to fully comply with FDA regulations at every stage of drug development and commercialization. From initial transgenic mouse studies to the FDA fatality investigation, this case study introduces all the key regulations and practices that govern the development, manufacture, and marketing of a new drug, including: [1] FDA Investigational and New Drug Application Processes, [2] FDA Code of Federal Regulations' current Good Manufacturing Practice (cGMP), [3] ISPE Good Automated Manufacturing Practice (GAMP) Readers will also be introduced to a variety of managers and researchers whose personal agendas conflict with best practices and therefore compromise the safety and effectiveness of a new drug product. Throughout the case study, the author offers tested and proven practices and tips so that these human flaws are not translated into drug product flaws. These practices and tips are critical and typically can only be learned through years of experience working in competitive drug development environments. A History of a cGMP Medical Event Investigation is ideal for students in biotechnology, pharmacology, engineering, and business management as well as professionals in biomedical and drug development. All readers will discover what can go wrong in developing and bringing a new drug to market. Most importantly, they will also learn how to apply Six Sigma principles and methods to ensure safe and effective product design, development, and manufacturing.
588 $a Description based on print version record.
610 1 2 $a United States. $b Food and Drug Administration. $3 758649
650 1 2 $a Adverse Drug Reaction Reporting Systems $z United States. $3 832845
650 2 2 $a Drug Therapy $x adverse effects $z United States. $3 2147336
650 2 2 $a Investigational New Drug Application $z United States. $3 2147337
650 0 $a Drugs $x Side effects. $3 789547
856 4 0 $u http://onlinelibrary.wiley.com/book/10.1002/9781118494943